Previous Article
Liminal BioSciences to report Q3 2019 results and hold conference call
Liminal BioSciences to report Q3 2019 results and hold conference call

Next Flipbook
Quarterly Report 2018 Q3
Quarterly Report 2018 Q3

Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manuf...